Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Licensing
-
By Jason Derry — Research and Markets recently announced the availability of two new reports relating to the biotechnology industry: "Biotechnology in the United States" and "Biopartnering Strategies: Maximizing Returns from Biotechnology Deal-making." According to the Research and Markets website, "Biotechnology in the United States" provides data and analysis relating to trends and…
-
By Kevin Noonan — Back in the 1970's, Firesign Theater had a comedy album entitled "Everything You Know is Wrong." This seems to be the Supreme Court's current opinion on the Federal Circuit; the Court hasn't actually affirmed a CAFC decision since J.E.M. Ag Supply v. Pioneer Hi-Bred Int'l. Inc. in 2001. The…
-
By Jason Derry — Genentech and Seattle Genetics have announced an agreement involving the development and commercialization of a humanized monoclonal antibody for treating hematologic malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. The antibody, SGN-40, is currently in Phase I and II clinical trials. According to the press release, Seattle…
-
By Jason Derry — Roche Holding AG has announced an agreement with Synosis Therapeutics in which Synosis will have rights to five drug candidates that Roche is no longer developing. Four of the drugs are in Phase I clinical trials. According to the Press Release, the drugs relate to schizophrenia, cognitive disorders, Parkinson's…
-
By Jason Derry — Elusys Therapeutics, Inc. has announced an exclusive license with Pfizer Inc. to collaborate in the development of new therapeutics for infectious diseases. The agreement relates to the use of Elusys' HP Antibody® technology. Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular…
-
By Jason Derry — Pharmacopeia and Wyeth have announced that the two companies have agreed to an exclusive license relating to the development and commercialization of therapeutics from Pharmacopeia's JAK3 inhibitor technology. Under the agreement, Pharmacopeia has the right to therapeutics relating to dermatological and ocular diseases by topical administration, while Wyeth has…
-
By Jason Derry — Amgen Inc. has announced that it will collaborate with Cytokinetics to generate small-molecule therapeutics for treating heart failure. In particular, the agreement relates to discovery, development, and commercialization of compounds that activate cardiac myosin. Cytokinetics has identified a particular cardiac myosin activator, CK-1827452, that is currently its lead drug…
-
By Jason Derry — Sigma-Aldrich has announced that it has agreed to give Pfizer a non-exclusive, worldwide license to use DNA-directed RNAi (ddRNAi) for research purposes. Sigma-Aldrich has an exclusive license to the ddRNAi technology (excluding the right to develop ddRNAi for therapeutic use in humans) from Benitec Ltd. and Australia's CSIRO (Commonwealth…
-
By Jason Derry — Crucell N.V. has announced a cross-licensing agreement with Merck & Co. relating to Crucell's vaccine technology. The deal allows Merck to use Crucell's technology in certain vaccine fields that have yet to be publicly disclosed, while Crucell will be able to manufacture its Advac®-based vaccines on a larger scale…
-
BASF Prevails in Seed-Saving Infringement Case By Robert Dailey — A federal district court held that a farmer who saved rice seed in violation of BASF's standard Stewardship Agreement infringed the patents covering the seed and its use. The buyer of the saved seed, however, had never actually signed the Stewardship Agreement covering…
Patent Docs 